Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and Tisagenlecleucel

BACKGROUND AND OBJECTIVE: Enthusiasm for the use of outcomes-based managed entry agreements (OBMEAs) to manage uncertainties apparent at the time of appraisal/pricing and reimbursement of new medicines has waned over the past decade, as challenges in establishment, implementation and re-appraisal ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Facey, Karen M., Espin, Jaime, Kent, Emma, Link, Angèl, Nicod, Elena, O’Leary, Aisling, Xoxi, Entela, van de Vijver, Inneke, Zaremba, Anna, Benisheva, Tatyana, Vagoras, Andrius, Upadhyaya, Sheela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8260322/
https://www.ncbi.nlm.nih.gov/pubmed/34231135
http://dx.doi.org/10.1007/s40273-021-01050-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8260322/
https://www.ncbi.nlm.nih.gov/pubmed/34231135
http://dx.doi.org/10.1007/s40273-021-01050-5

Ejemplares similares